VistaGen reports Phase 3 fasedienol shows positive efficacy signal in severe social anxiety subgroup analysis
VTGN•Subgroup analysis points to severe social anxiety patients
Data highlight a positive efficacy signal in public speaking challenge participants with very severe social anxiety disorder.
Readout targets acute treatment positioning, supporting the investment case for its lead intranasal pherine program.
Phase 3 fasedienol data to be presented at Psych Congress 2026
VistaGen set a Psych Congress 2026 poster for Sept. 17-18 in New Orleans on Phase 3 fasedienol nasal spray data.
Results have not been presented yet; the company plans to disclose subgroup analyses at the meeting.
